Optimizing Novel Therapies and Surgery in Ear...

AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)

Up next

Day 5: Top Takeaways From ASCO26

Dr. Monty Pal shares highlights from the final day of ASCO26, including new research on treating anemia in myelofibrosis, advances in RAS-mutated mCRC, novel therapies for AML, and a potentially practice-changing trial in TNBC. LINK TO FULL TRANSCRIPT

. 9min 35sec

Day 4: Top Takeaways From ASCO26

Dr. Monty Pal shares highlights from Day 4 of the 2026 ASCO Annual Meeting, including a much-anticipated study in hepatocellular carcinoma, new data in non–small cell lung cancer, and a key update in the treatment of Merkel cell carcinoma. LINK TO TRANSCRIPT

. 8min 45sec

Recommended Episodes

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2024.1

ASCO Guidelines

Dr. Jyoti Patel discusses the latest update to the stage IV NSCLC with driver alterations living guideline, specifically for patients with EGFR or ROS1 alterations. She shares the latest recommendations based on recently published evidence, such as the FLAURA2, MARIPOSA-2, and TR ... Show more

. 12min 24sec

Systemic Therapy for SCLC: ASCO-OH (CCO) Guideline

ASCO Guidelines

Dr. Greg Kalemkerian joins us on the ASCO Guideline Podcast to discuss the newest ASCO – Ontario Health (Cancer Care Ontario) Guideline on systemic therapy for small-cell lung cancer (SCLC). He reviews the evidence-based recommendations from the panel, including guidance on syste ... Show more

. 27min 13sec

Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of CAP Guideline

ASCO Guidelines

Dr. Praveen Vikas, Dr. Tyler Johnson, and Dr. Russell Broaddus present the ASCO endorsement of the Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Associa ... Show more

. 16min 31sec

Endocrine and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer – Capivasertib-Fulvestrant: Rapid Guideline Update

ASCO Guidelines

Dr. Angela DeMichele, Dr. Lynn Henry, and Dr. Harold Burstein present the latest breast cancer rapid recommendation update impacting two ASCO guidelines. This update focuses on the new option, capivasertib plus fulvestrant, for patients with hormone receptor-positive, HER2-negati ... Show more

. 14min 9sec